Litcius/Paper detail

First-line PARP inhibition in ovarian cancer — standard of care for all?

Susana Banerjee, Christopher J. Lord

2020Nature Reviews Clinical Oncology35 citationsDOI

Topics & Concepts

OlaparibPoly ADP ribose polymeraseOvarian cancerPARP inhibitorOncologyInternal medicinePolymeraseFirst lineMedicineCancer researchCancerBiologyGeneticsDNAPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentPlant Virus Research Studies
First-line PARP inhibition in ovarian cancer — standard of care for all? | Litcius